AI MARKET SCANNING

Cabaletta Bio, Inc.

🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP -0.32%
MAX GAP RECORD -27.50%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $CABA
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Aug 10, 2026 Earnings Release 2026-08-10 (BEFORE OPEN)
-0.36%
May 13, 2026 Earnings Release 2026-05-13 (BEFORE OPEN)
-0.83%
Mar 23, 2026 Earnings Release 2026-03-23 (BEFORE OPEN)
+6.12%
Nov 10, 2025 Earnings Release 2025-11-10 (BEFORE OPEN)
+0.78%
Aug 07, 2025 Earnings Release 2025-08-07 (BEFORE OPEN)
-0.69%
May 15, 2025 Earnings Release 2025-05-15 (BEFORE OPEN)
+7.69%
Nov 14, 2024 Earnings Release 2024-11-14 (BEFORE OPEN)
+1.50%
Aug 08, 2024 Earnings Release 2024-08-08 (BEFORE OPEN)
-27.50%

VOLATILITY & GAP BIAS

AVG GAP MOVE 4.5%
Bullish Gaps (5)
Bearish Gaps (2)
Neutral / Flat (7)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $CABA

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗